NEW YORK (GenomeWeb News) – Roche disclosed after the close of the market on Tuesday that the US Federal Trade Commission has requested additional information related to its $5.7 billion hostile bid for Illumina.

The request was issued pursuant to the Hart-Scott-Rodino Antitrust Improvements Act and seeks more information about Roche's microarray business, the company said.

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.